The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.

This is an open-label, dose escalation trial designed to assess safety and tolerability of 4 dose strengths and 1-2 cycles of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.

Inclusion Criteria:

• Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.
• Have at least one Metastases to the Choroid in the study eye

Exclusion Criteria:

• Active ocular infection or disease.
• Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.
• Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment